celyad 2020

2.133 Posts, Pagina: « 1 2 3 4 5 6 ... 102 103 104 105 106 107 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
De koers beweegt amper, is het in afwachting deze maand? -of is het een grote surprise?
Ja twin ,begrijp de frustratie maar we hebben er geen invloed op en op dit forum is ook weinig te lezen. Je moet maar wachten dan tot eind mei.
Celyad (CYAD)

Moving right along, we come across Celyad, which is developing innovative CAR-T NK cell-based immunotherapies that could potentially treat cancer. As the second half of 2020 will feature major catalysts, it’s no wonder the analyst community is excited about this name.

In the near-term, Celyad will present updated data from the Phase I alloSHRINK study of CYAD-101, its therapy designed as a treatment for mCRC, at the virtual ASCO conference on May 29 through 31. Using non-gene editing technology, the therapy has already shown anti-tumor activity in two out of twelve patients with a partial response and five patients with stable disease with a minimum of three months of duration.

Representing H.C. Wainwright, five-star analyst Edward White is optimistic that the outcome will be favorable. He explained, “To date, CYAD-101 alloSHRINK has not demonstrated clinical evidence of GvHD or dose limiting toxicities.”

Looking forward, CYAD will read out preliminary data from the Phase 1 THINK trial involving its candidate, CYAD-01, a CAR-T that uses natural killer cell specificity to target T-cells against a broad range of tumors, without preconditioning in patients with r/r AML and MDS, and the DEPLETHINK trial utilizing preconditioning with Cy/Flu. Both of these trials use the OptimAb manufacturing process, but White points out that the company will decide which protocol to proceed with based on the data.

Some investors expressed concern after COVID-19 forced the company to push back the previously expected timing for the THINK and DEPLETHINK trial readouts, but White was unphased by the delay. “THINK data presented at the American Society of Hematology (ASH) Annual Meeting 2019 showed that 53% (8/15) of evaluable patients demonstrated anti-leukemic activity with bone marrow blasts decrease, including five patients with objective responses and one patient with stable disease (SD) for at least three months,” he stated. The analyst added, “No objective responses had been shown at the time of presentation, but safety data demonstrated that CYAD-01 manufactured with OptimAb was well tolerated following preconditioning chemotherapy.”

With a decision on which protocol CYAD will pursue expected by year end 2020, the deal is sealed for White. In addition to reiterating his Buy recommendation, he kept the $37 price target as is. This target conveys his confidence in CYAD’s ability to soar 339% in the next year. (To watch White’s track record, click here)

All in all, other analysts echo White’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $27.33 average price target, the upside potential comes in at 224%. (See Celyad stock analysis on TipRanks)

Twin schreef op 22 mei 2020 19:17:

@garre nog een dikke week geduld en zullen zien waar we staan

Wat is er over een week Twin? Conferentie?
Celyad presenteert update van CYAD-101 voor geavanceerde colorectale kanker en shRNA-platform van de volgende generatie op het ASCO Virtual Scientific Program 2020
Hopelijk stijgen, maar het beurssentiment zal een flinke vinger in de pap hebben. Tiprank bericht geeft moed.
2.133 Posts, Pagina: « 1 2 3 4 5 6 ... 102 103 104 105 106 107 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum


Vertraagd 25 mei 2020 17:35
Koers 7,830
Verschil +0,180 (+2,35%)
Hoog 7,890
Laag 7,630
Volume 19.703
Volume gemiddeld 48.468
Volume gisteren 13.987

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: VWD Group